Literature DB >> 20008180

Alpha thalassemia major--new mutations, intrauterine management, and outcomes.

Elliott P Vichinsky1.   

Abstract

Alpha thalassemia disorders are a group of hereditary anemias caused by absent or decreased production of the alpha chain of hemoglobin. Hemoglobin Bart's hydrops fetalis is usually a fatal in-utero disease caused by absence of the alpha genes. However, the molecular and genotypic expression of hemoglobin Bart's varies and increasing numbers of births are being reported. Population screening and prenatal diagnosis of at-risk couples is essential but often not performed. Most affected pregnancies are often undetected, resulting in severe fetal and maternal complications. Noninvasive monitoring by Doppler ultrasonagraphy with intrauterine transfusion therapy has changed the prognosis for this disorder. These advances in intrauterine and postnatal therapy have resulted in ethical dilemmas for the family and the provider.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008180     DOI: 10.1182/asheducation-2009.1.35

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  16 in total

1.  Normal cognitive functioning in a patient with Hb Bart's hydrops successfully cured by hematopoietic SCT.

Authors:  B Pongtanakul; K Sanpakit; V Chongkolwatana; V Viprakasit
Journal:  Bone Marrow Transplant       Date:  2013-08-26       Impact factor: 5.483

Review 2.  Clinical manifestations of α-thalassemia.

Authors:  Elliott P Vichinsky
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

3.  Development and clinical implementation of a combination deletion PCR and multiplex ligation-dependent probe amplification assay for detecting deletions involving the human α-globin gene cluster.

Authors:  Benjamin R Kipp; Samantha E Roellinger; Patrick A Lundquist; W Edward Highsmith; D Brian Dawson
Journal:  J Mol Diagn       Date:  2011-06-25       Impact factor: 5.568

Review 4.  Biomaterials in fetal surgery.

Authors:  Sally M Winkler; Michael R Harrison; Phillip B Messersmith
Journal:  Biomater Sci       Date:  2019-05-17       Impact factor: 6.843

Review 5.  Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia.

Authors:  Cheryl Mensah; Sujit Sheth
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 6.  The transfusion management of beta thalassemia in the United States.

Authors:  Ashutosh Lal; Trisha Wong; Siobán Keel; Monica Pagano; Jong Chung; Aditi Kamdar; Latha Rao; Alan Ikeda; Geetha Puthenveetil; Sanjay Shah; Jennifer Yu; Elliott Vichinsky
Journal:  Transfusion       Date:  2021-08-28       Impact factor: 3.337

7.  Reliable detection of paternal SNPs within deletion breakpoints for non-invasive prenatal exclusion of homozygous α-thalassemia in maternal plasma.

Authors:  Ti-Zhen Yan; Qiu-Hua Mo; Ren Cai; Xue Chen; Cui-Mei Zhang; Yan-Hui Liu; Ya-Jun Chen; Wan-Jun Zhou; Fu Xiong; Xiang-Min Xu
Journal:  PLoS One       Date:  2011-09-29       Impact factor: 3.240

8.  A Case of Nonimmune Hydrops Fetalis Caused by Homozygous α-Thalassemia.

Authors:  Melek Akar; Dilek Dilli; Uğur Dilmen
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

9.  Pregnancy with a severe hemoglobinopathy: unintended consequences of transfusions.

Authors:  David Kim; Hector Mendez-Figueroa; Brenna L Anderson
Journal:  Case Rep Obstet Gynecol       Date:  2013-01-27

Review 10.  Desferrithiocin: a search for clinically effective iron chelators.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti
Journal:  J Med Chem       Date:  2014-09-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.